MHRA approves Pfizer-BioNTech’s Comirnaty JN.1 vaccine
The approval encompasses four variations of the Comirnaty JN.1 vaccine, following the International Recognition Procedure.
Themes
The potential of 3D printing in drug development and delivery
How NVIDIA grew with the healthcare market instead of pushing into it
CytoReason secures $80m investment for AI expansion
Gene therapy: How Veristat cut trial database costs by 30%
Drug development costs predicted to soar as BIOSECURE Act gains momentum
SOTIO partners with Biocytogen to expand ADC oncology pipeline
Aspect wins $72.75m from Canadian government for bioprinted pipeline
